Right Brain Bio develops disease‑modifying therapies for Parkinson’s by targeting excess intracellular dopamine, the identified driver of neurodegeneration. Its lead candidate, RB‑190, is an oral small‑molecule that lowers neuronal dopamine accumulation without depleting extracellular levels and has entered Phase 2 trials with FDA‑backed data supporting safety and target engagement.
Funding
Funding not disclosed
Founders
Product
Problem
Current Parkinson’s therapies target dopamine deficiency, yet simply increasing dopamine levels does not halt disease progression and patients continue to experience neurodegeneration and disability.
Solution
Right Brain Bio has identified excess dopamine inside neurons as the primary driver of Parkinson’s neurodegeneration. The company has developed RB‑190, a small‑molecule agent that reduces intracellular dopamine accumulation, thereby protecting dopaminergic neurons from toxic stress. Preclinical studies demonstrated reversal of dopamine‑induced cellular damage, and the FDA has accepted the data package, allowing RB‑190 to enter Phase 2 clinical trials. By addressing the underlying pathogenic mechanism rather than symptomatic dopamine replacement, RB‑190 aims to modify disease progression and improve functional outcomes for patients.
Target Audience
Primary customers are pharmaceutical partners and clinical research organizations developing disease‑modifying therapies for Parkinson’s disease, as well as neurologists and movement‑disorder clinics seeking next‑generation treatment options.
Features
- Novel mechanism that selectively lowers intracellular dopamine without depleting extracellular neurotransmitter levels
- Small‑molecule oral formulation designed for blood‑brain barrier penetration and sustained neuronal exposure
- FDA‑acknowledged data package supporting entry into Phase 2 trials, including safety, pharmacokinetics, and target‑engagement biomarkers
- Integrated biomarker strategy using cerebrospinal fluid and imaging endpoints to monitor intracellular dopamine reduction
- Adaptive clinical‑trial design leveraging Bayesian statistics to accelerate efficacy assessment